טוען...
CDK 4/6 inhibitors mired in uncertainty in HR positive and HER2 negative early breast cancer
Cell-cycle abnormalities are common in estrogen receptor- and/or progesterone receptor-positive, and HER2-non-overexpressing (HR+/HER2-) breast cancer, and have long been considered potential therapeutic targets. Cyclin-dependent kinase (CDK) 4/6 inhibitors have dramatically changed the therapeutic...
שמור ב:
| הוצא לאור ב: | Breast |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7758367/ https://ncbi.nlm.nih.gov/pubmed/33352521 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.breast.2020.12.006 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|